Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2365 - Prognostic value of MRI-derived residual retropharyngeal lymph node after intensity-modulated radiotherapy in nasopharyngeal carcinoma and a nomogram for the prediction of it

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Wang-Zhong Li

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

W. Li1, H. Liang2, X. Lv2, L. Ke3, Y. Ye4, Y. Yu2, W. Qiu2, G. Liu2, X. Huang1, K. Liu2, S. Lv2, X. Guo2, Y. Xiang2, W. Xia2

Author affiliations

  • 1 Department Of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN
  • 2 Department Of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou/CN
  • 3 Department Of Radiology, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN
  • 4 Clinical Trial Design Division, Sun Yat-Sen Memorial Hospital, Guangzhou/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2365

Background

In nasopharyngeal carcinoma (NPC) patients with retropharyngeal lymph node (RLN) metastasis who receive intensity-modulated radiotherapy (IMRT), the incidence of magnetic resonance imaging (MRI)-derived residual retropharyngeal lymph node (RRLN) is not rare and its prognostic value is uncertain. In present study, we aim to investigate the prognostic value of MRI-derived RRLN and sought to develop a nomogram for the prediction of it.

Methods

A total of 922 patients with RLN metastasis without distant metastasis NPC treated with IMRT were enrolled in present study. The Kaplan-Meir survival curves and cox proportional regression model were used to assess the prognostic value of RRLN. The patients were then randomly assigned into the training cohort (n = 645) and the validation cohort (n = 277). Factors significantly associated with RRLN were identified and used to construct nomogram with multivariate logistic regression model. The discrimination and performance of nomogram were evaluated in training cohort and confirmed in validation cohort.

Results

The incidence of RRLN was 28.2%. The 5-year OS, DFS, DMFS, LRRFS of the RRLN group and non-RRLN group were 84.1% vs. 93.2%, 65.1% vs. 87.3%, 71.2% vs. 94.2% and 87.8% vs. 95.6%, respectively (for all rates, P < 0.05). Necrosis, extra-nodal neoplastic spread (ENS), minimum axial dimeter (MAD) and the percentage volume of the GTVnx receiving 95% of the prescribed dose (GTVnx V95%) were identified as independent factors associated with RRLN and used to construct the nomogram. The nomogram showed favorable calibration and discrimination in training cohort (AUC, 0.746) and validation cohorts (AUC, 0.738). Patients with high-risk scores had a higher probability of developing RRLN than patients with low-risk scores in training cohort (OR, 5.183, 95% CI 2.845-8.525) and validation cohort (OR, 6.977, 95% CI 3.990-12.200).

Conclusions

MRI-derived RRLN was a negative independent prognostic factor for OS, PFS, DMFS and LRRFS in NPC patients with RLN metastasis who received IMRT. We constructed a nomogram based on clinical and radiological characteristics that predicted an individual's risk of RRLN.

Clinical trial identification

Legal entity responsible for the study

Sun Yat-sen University Cancer Center.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.